responsif GmbH Starting To Recruit Patients With Renal Cell Carcinoma For A Clinical Study
10/19/2005 5:11:31 PM
The biotechnology company responsif GmbH announced today that it was initiating the first clinical trials of an innovative immunotherapy it has developed for the treatment of renal cell carcinoma. Recruitment of patients for the clinical trial can now get underway. The aim of the new therapeutic concept is to activate the body’s own endogenous immune defenses against tumor cells via immunization. The first clinical trial performed to test the new method will take place at the Medical Division III of the University of Erlangen-Nürnberg; this division is headed by Medical Director Prof. Jochen R. Kalden. The university-affiliated Division of Urology at Waldkrankenhaus in Erlangen (Medical Director: Prof. Karl M. Schrott) and the Blood Donation Service of the German Red Cross in Nürnberg (Medical Director and Managing Director: Dr. Franz Weinauer) will also participate in the study. The objective of the first clinical trial will be to investigate the tolerability of the new method.
comments powered by